- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06520826
Vafseo Outcomes In-Center Experience (VOICE)
Sikkerhed af tre gange ugentlig oral Vadadustat til behandling af anæmi hos hæmodialyse-emner: Vafseo-resultater i center-oplevelse
This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will obtain long-term safety data in a large sample of subjects receiving in-center hemodialysis to support adoption of three times per week vadadustat dosing.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Colorado
-
Lone Tree, Colorado, Forenede Stater, 80124
- USRC Kidney Research
-
-
Georgia
-
Dalton, Georgia, Forenede Stater, 30720
- Nephrology and Hypertension Specialists, PC
-
-
New Mexico
-
Gallup, New Mexico, Forenede Stater, 87301
- US Renal Care - Gallup
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230
- Dallas Renal Group
-
Live Oak, Texas, Forenede Stater, 78233
- US Renal Care - Live Oak
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adult patients greater than or equal to 18 years of age.
- Receiving outpatient in-center hemodialysis at least three times per week for end-stage kidney disease.
- Currently prescribed or eligible for erythropoiesis-stimulating agent based on approved facility policy
- Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure.
Exclusion Criteria:
- Contraindication to receive vadadustat or any of its known constituents per USPI.
- Cirrhosis or active, acute liver disease. Concomitant use of any hypoxia-inducible factor prolyl-hydroxylases or OAT1/OAT3 inhibitors (probenacid, rifampicin, gemfibrozil, or teriflunomide).
- Unable to comply with study requirements or in the opinion of a healthcare provider or a member of the central study team, not clinically stable to participate in the study.
- Pregnant at time of consent (per subject self-report).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Vadadustat
Vadadustat, 300 mg tablets, administered orally three times per week |
A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Andre navne:
|
|
Aktiv komparator: Erythropoiesis-stimulating agent (ESA) - Standard of Care (SOC)
Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp) administered as per standard of care |
Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Combination of the hierarchical endpoints of all-cause mortality and all-cause hospitalization.
Tidsramme: 18 months
|
The hierarchical endpoints of all-cause mortality and all cause hospitalization will be analyzed by the win odds method with ranking all cause mortality more important than all cause hospitalization. |
18 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
All-cause hospitalization
Tidsramme: 18 months
|
All-cause hospitalization |
18 months
|
|
All-cause mortality
Tidsramme: 18 months
|
All-cause mortality |
18 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Peptider
- Aminosyrer, peptider og proteiner
- Proteiner
- Farmakologiske handlinger
- Kemiske handlinger og anvendelser
- Terapeutiske anvendelser
- Biologiske faktorer
- Kulhydrater
- Intercellulære signalpeptider og proteiner
- Glycoproteiner
- Glycoconjugates
- Kolonistimulerende faktorer
- Hæmatopoietiske cellevækstfaktorer
- Cytokiner
- Erythropoietin
- Hæmatologiske midler
- Epoetin Alfa
- Darbepoetin alfa
- Hæmatinik
- Kontinuerlig erythropoietin receptoraktivator
- Vadadustat
Andre undersøgelses-id-numre
- USRC-2024-001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .